Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 14, 2022

SELL
$26.43 - $34.5 $1.05 Million - $1.37 Million
-39,764 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$22.71 - $36.69 $903,040 - $1.46 Million
39,764 New
39,764 $1.19 Million

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $935M
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Mission Creek Capital Partners, Inc. Portfolio

Follow Mission Creek Capital Partners, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Mission Creek Capital Partners, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Mission Creek Capital Partners, Inc. with notifications on news.